Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067737 · ClinicalTrials.gov registry record · Phase 2
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
A Phase 2 study of Opioid Use Disorder, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06067737: Recruiting Phase 2 study of Opioid Use Disorder, sponsored by Johns Hopkins University.
NCT06067737 is a Phase 2 study of Opioid Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 90 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06067737, a Phase 2 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with outpatient buprenorphine maintenance, quality of life, and mood.
Primary Outcome
Non-buprenorphine opioid abstinence as verified by urine toxicology at each visit and Timeline Follow Back (TLFB). These will be combined to assess opioid abstinence for each participant. These will be assessed at the 8-week timepoint for the previous 3-weeks. Missing values will be presumed positive. Timeline Follow Back (TLFB) for Opioids: This is a self-report of drug use per day. This procedure asks participants to retrospectively quantitate their use of drugs. Greater numbers indicate more
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
What NCT06067737 shows while recruiting
NCT06067737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06067737 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06067737 about?
NCT06067737 is a clinical study titled "Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder". This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone b...
What is the current status of trial NCT06067737?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-02-08. Estimated completion is 2029-05.
What conditions does trial NCT06067737 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06067737?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06067737?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06067737 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06067737's enrollment target sits among peer trials
90 138th of 257 higher than 119 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI